Development of a modified gp130 ligand to treat obesity-induced insulin resistance

IC7是两种天然存在的蛋白质--CNTF和IL-6的混合物。这些gp130受体配体已被证明对人类具有积极的代谢作用，但单独而言，它们不适合用于治疗。IC7是这项技术所基于的新分子，它是CNTF和IL-6在特定设计中的组合，以避免负面影响。初步结果表明，IC7具有积极的代谢作用，但需要进一步开发以提高其在治疗胰岛素抵抗和2型糖尿病方面的有效性。

IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.